Collaboration will combine Vyriad’s lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ — Vyriad, Inc., a clinical-stage biotechnology company developing the next...
In a significant development for cancer treatment, the US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ CAR-T cell therapy for adult patients with relapsed or treatment-resistant B cell precursor acute lymphoblastic leukemia (B-ALL). This...
— The T cell therapy company heads to ASH 2024 next month to introduce its novel allogeneic protection and cytokine engineering strategies to support the development of potent and persistent off-the-shelf UNi-T cells — Notch Therapeutics, Inc., a biotechnology company...
In a groundbreaking advancement, three individuals suffering from severe autoimmune diseases have achieved remission after receiving a revolutionary therapy using donor-derived immune cells. This pioneering treatment, which utilized bioengineered immune cells known as...
U.K. developer Quell Therapeutics hired eXmoor Pharma to make supplies of its pipeline of novel immunosuppressive cell therapies—called CAR-Tregs—at its new cell and gene therapy facility. Quell recently teamed with fellow U.K.-based eXmoor in a “strategic...
